1. Home
  2. TVAI vs OLMA Comparison

TVAI vs OLMA Comparison

Compare TVAI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVAI
  • OLMA
  • Stock Information
  • Founded
  • TVAI 2024
  • OLMA 2006
  • Country
  • TVAI United States
  • OLMA United States
  • Employees
  • TVAI N/A
  • OLMA N/A
  • Industry
  • TVAI
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • TVAI
  • OLMA Health Care
  • Exchange
  • TVAI NYSE
  • OLMA Nasdaq
  • Market Cap
  • TVAI 271.4M
  • OLMA 299.7M
  • IPO Year
  • TVAI 2025
  • OLMA 2020
  • Fundamental
  • Price
  • TVAI $10.00
  • OLMA $4.65
  • Analyst Decision
  • TVAI
  • OLMA Strong Buy
  • Analyst Count
  • TVAI 0
  • OLMA 4
  • Target Price
  • TVAI N/A
  • OLMA $24.50
  • AVG Volume (30 Days)
  • TVAI 62.1K
  • OLMA 825.6K
  • Earning Date
  • TVAI 01-01-0001
  • OLMA 08-05-2025
  • Dividend Yield
  • TVAI N/A
  • OLMA N/A
  • EPS Growth
  • TVAI N/A
  • OLMA N/A
  • EPS
  • TVAI N/A
  • OLMA N/A
  • Revenue
  • TVAI N/A
  • OLMA N/A
  • Revenue This Year
  • TVAI N/A
  • OLMA N/A
  • Revenue Next Year
  • TVAI N/A
  • OLMA N/A
  • P/E Ratio
  • TVAI N/A
  • OLMA N/A
  • Revenue Growth
  • TVAI N/A
  • OLMA N/A
  • 52 Week Low
  • TVAI $10.02
  • OLMA $2.86
  • 52 Week High
  • TVAI $10.18
  • OLMA $16.62
  • Technical
  • Relative Strength Index (RSI)
  • TVAI N/A
  • OLMA 52.46
  • Support Level
  • TVAI N/A
  • OLMA $4.38
  • Resistance Level
  • TVAI N/A
  • OLMA $5.01
  • Average True Range (ATR)
  • TVAI 0.00
  • OLMA 0.30
  • MACD
  • TVAI 0.00
  • OLMA 0.05
  • Stochastic Oscillator
  • TVAI 0.00
  • OLMA 63.64

About TVAI THAYER VENTURES ACQUISITION CORP II

Thayer Ventures Acquisition Corp II is a blank check company.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: